roche-logo-blue.png
Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics
June 28, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s...
roche-logo-blue.png
Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options
June 16, 2022 01:03 ET | F. Hoffmann-La Roche Ltd
Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV). 1Nearly...
roche-logo-blue.png
Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease
June 16, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease For more than a decade Roche has been working in...
roche-logo-blue.png
Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and quantitatively measure viral load levels of COVID-19
June 15, 2022 11:45 ET | F. Hoffmann-La Roche Ltd
The cobas SARS-CoV-2 Duo test combines the standard qualitative result of a traditional SARS-CoV-2 PCR test with a quantitative result, which measures the viral load of a patient suspected of...
roche-logo-blue.png
Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
June 10, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with...
roche-logo-blue.png
U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
June 09, 2022 01:03 ET | F. Hoffmann-La Roche Ltd
FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom treatment with Rozlytrek may be...
roche-logo-blue.png
European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
June 09, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive...
roche-logo-blue.png
European Commission approves Roche’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma
June 08, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Lunsumio® (mosunetuzumab) is the first CD20xCD3 T-cell engaging bispecific antibody available to treat the most common slow-growing form of non-Hodgkin lymphoma, follicular lymphoma (FL)Lunsumio...
roche-logo-blue.png
FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
May 31, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk Prescribing information updated with FIREFISH...
roche-logo-blue.png
New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
May 27, 2022 01:00 ET | F. Hoffmann-La Roche Ltd
Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma...